<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01423032</url>
  </required_header>
  <id_info>
    <org_study_id>WISP_RI05</org_study_id>
    <nct_id>NCT01423032</nct_id>
  </id_info>
  <brief_title>Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL)</brief_title>
  <official_title>Bendamustine Versus Fludarabine as 2nd-line Treatment in Chronic Lymphocytic Leukemia, Stage BINET B+C / RAI II-IV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>WiSP Wissenschaftlicher Service Pharma GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Klinikum Leverkusen gGmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ribosepharm GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mundipharma Research GmbH &amp; Co KG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>WiSP Wissenschaftlicher Service Pharma GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bendamustine demonstrated clinical activity in pre-treated hematological malignancies due to
      its unique mechanism of action distinct from standard alkylating agents. This study assesses
      its efficacy in patients with chronic lymphocytic leukemia pre-treated with an alkylator, in
      comparison to fludarabine.

      Patients with relapsed chronic lymphocytic leukemia requiring treatment after one previous
      systemic regimen (usually chlorambucil-based) are randomized to either receive bendamustine
      100 mg/m² on days 1 and 2 of a 4-week cycle, or standard fludarabine treatment consisting of
      25 mg/m² on days 1 to 5 every four weeks. The primary objective was to achieve non-inferior
      progression-free survival with bendamustine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>the patients were followed on average for 36 months</time_frame>
    <description>individual time-frame up to max. follow-up (Kaplan-Meier estimation)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Bendamustine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fludarabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bendamustine</intervention_name>
    <description>100 mg/m² iv, day 1+2, q4w</description>
    <arm_group_label>Bendamustine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>25 mg/m² iv, days 1-5, q4w</description>
    <arm_group_label>Fludarabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically or immunologically confirmed chronic B-cell leukemia

          -  refractory (i.e. no response or progression during initial chemotherapy) or relapsed
             situation after first-line treatment regimen

          -  disease stage II-IV according to Rai or B/C according to Binet staging system,
             respectively

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 3 or better

          -  negative pregnancy test/ adequate method of contraception

        Exclusion Criteria:

          -  T-CLL, PLL (prolymphocytic leukemia)

          -  presence of Richter's transformation

          -  first-line treatment containing either fludarabine or bendamustine

          -  acute infections or distinctly reduced organ function precluding the application of
             chemotherapy, as for pulmonary, heart, liver (total bilirubin &gt; 5mg/dl), renal system
             (creatinine &gt; 2 mg/dl), or metabolic disorders

          -  secondary malignancy (except for curative treated basal cell carcinoma or cervical
             cancer)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norbert Niederle, Prof, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Med. Klinik III, Klinikum Leverkusen gGmbH, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prof. Dr. Norbert Niederle</name>
      <address>
        <city>Leverkusen</city>
        <state>NRW</state>
        <zip>D-51375</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2011</study_first_submitted>
  <study_first_submitted_qc>August 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2011</study_first_posted>
  <last_update_submitted>August 24, 2011</last_update_submitted>
  <last_update_submitted_qc>August 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relapsed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

